$RDY · DR REDDYS LABORATORIES LTD
Dr. Reddy's reported Q2 FY2027 IFRS results. Revenue fell 1.5% YoY to ₹86,708 Mn, gross margin was 52.1% versus 54.7% a year ago, and profit attributable to equity holders dropped 36% YoY to ₹9,250 Mn. Diluted EPS was ₹11.10.
- Q2 revenue ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ.
- Profit attributable to equity holders dropped 36% YoY to ₹9,250 Mn.
- North America revenue fell 23% YoY to ₹24,890 Mn.
- India revenue rose 17% YoY to ₹18,508 Mn.
- Gross margin recovered to 52.1% from Q1FY27's 46.5%.
Shares slipped 0.40% since filing to $13.23 from $13.29, suggesting muted concern despite the profit drop.
Branded-market growth and sequential margin recovery counterbalance a steep North America decline and unresolved manufacturing quality issues.
U.S. generics pricing pressure persists while branded India and emerging-markets growth offsets the decline.
Semaglutide API out-of-specification batches and USFDA Form 483s at Srikakulam and Bachupally create supply and compliance risk.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.